Last reviewed · How we verify
Neoadjuvant SNF Precision Therapy Phase III
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial designed to compare the efficacy and safety of neoadjuvant chemotherapy based on SNF classification with or without precision medicine agents in previously untreated patients with early-stage or locally advanced HR+/HER2- breast cancer.
Details
| Lead sponsor | Fudan University |
|---|---|
| Phase | PHASE3 |
| Status | RECRUITING |
| Enrolment | 404 |
| Start date | Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Apr 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Neoadjuvant Therapy
Interventions
- Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib
- Chemotherapy (wP-EC)
Countries
China